Author: Peter Norman, PhD, MBA

Figures:
Figure 1.1. Schematic of the Renin-Angiotensin-Aldosterone System
Figure 1.2. Schematic of the Coagulation Cascade
Figure 5.1. Development Status of Protease Inhibitors being Developed by Major Pharmaceutical Companies

Tables:
Table 2.1. Human Degradome by Catalytic Class
Table 2.2. A02 Family Aspartic Proteases
Table 2.3. A01 Family Aspartic Proteases
Table 2.4. A22 Family Aspartic Proteases
Table 2.5. S01 Serine Proteases that Affect the Coagulation Cascade
Table 2.6. S01 Kallikrein Serine Proteases
Table 2.7. S01 S01 Serine Proteases of the Complement System.
Table 2.8. S01 Trypsin-like Serine Proteases
Table 2.9. S01 Tryptase and Elastase-like Serine Proteases
Table 2.10. Other S01 Family Serine Proteases
Table 2.11. Sx2 Family Serine Proteases
Table 2.12. S09 Family Serine Proteases
Table 2.13. S08 Family Serine Proteases
Table 2.14. Serine Proteases from Other than the S01, Sx2, S08, and S09 Families
Table 2.15. Threonine Proteases
Table 2.16. Caspase Cysteine Proteases
Table 2.17. Cathepsin Cysteine Proteases
Table 2.18. Calpain Cysteine Proteases
Table 2.19. Ubiquitin Cysteine Proteases
Table 2.20. Non C01, C02, C14, and C19 Cysteine Proteases
Table 2.21. Aminopeptidase Metalloproteases
Table 2.22. Carboxypeptidase Metalloproteases
Table 2.23. Endopeptidase Metalloproteases
Table 2.24. Matrix Metalloproteases
Table 2.25. ADAM Family Metalloproteases
Table 2.26. ADAM-TS Family Metalloproteases
Table 2.27. M16, M19, M22, and M28 Family Metalloproteases
Table 2.28. Meta Zinc Metalloproteases
Table 4.1. Marketed ACE Inhibitors and 2007 Sales Revenues
Table 4.2. Marketed HIV Protease Inhibitors and 2007 Sales Revenues
Table 5.1. Protease Inhibitors in Development for Cardiovascular Diseases Other than Thrombosis
Table 5.2. Direct and Indirect Factor Xa Inhibitors in Development
Table 5.3. Thrombin Inhibitors in Development
Table 5.4. DPP-IV Inhibitors in Development
Table 5.5. Protease Inhibitors in Development for CNS Disorders
Table 5.6. Protease Inhibitors in Development for Inflammatory or Musculoskeletal Diseases
Table 5.7. Cathepsin K Inhibitors in Development
Table 5.8. Protease Inhibitors in Development for the Treatment of Cancer and Angiogenic Disorders
Table 5.9. Protease Inhibitors in Development for the Treatment of Viral Infections
Table 6.1. AstraZeneca's Protease Inhibitor Pipeline
Table 6.2. Bayer's Protease Inhibitor Pipeline
Table 6.3. Boehringer Ingelheim's Protease Inhibitor Pipeline
Table 6.4. Bristol-Myers Squibb's Protease Inhibitor Pipeline
Table 6.5. Eli Lilly's Protease Inhibitor Pipeline
Table 6.6. Merck's Protease Inhibitor Pipeline
Table 6.7. Novartis' Protease Inhibitor Pipeline
Table 6.8. Pfizer's Protease Inhibitor Pipeline
Table 6.9. Roche's Protease Inhibitor Pipeline
Table 6.10. sanofi-aventis' Protease Inhibitor Pipeline
Table 6.11. Schering Plough's Protease Inhibitor Pipeline
Table 6.12. Takeda's Protease Inhibitor Pipeline
Table 7.1. Protease Inhibitors in Late-stage Development and Anticipated NDA Filing Dates